Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Mar;95(3):995–1001. doi: 10.1172/JCI117809

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

D E Vaughan 1, S A Lazos 1, K Tong 1
PMCID: PMC441432  PMID: 7884001

Abstract

Plasminogen activator-inhibitor C-1 (PAI-1) plays a critical role in the regulation of fibrinolysis, serving as the primary inhibitor of tissue-type plasminogen activator. Elevated levels of PAI-1 are a risk factor for recurrent myocardial infarction, and locally increased PAI-1 expression has been described in atherosclerotic human arteries. Recent studies have shown that the administration of angiotensin converting enzyme inhibitors reduces the risk of recurrent myocardial infarction in selected patients. Since angiotensin II (Ang II) has been reported to induce PAI-1 production in cultured astrocytes, we have hypothesized that one mechanism that may contribute to the beneficial effect of angiotensin converting enzyme inhibitors is an effect on fibrinolytic balance. In the present study, we examined the interaction of Ang II with cultured bovine aortic endothelial cells (BAECs) and the effects of this peptide on the production of PAI-1. 125I-Ang II was found to bind to BAECs in a saturable and specific manner, with an apparent Kd of 1.4 nM and Bmax of 74 fmol per mg of protein. Exposure of BAECs to Ang II induced dose-dependent increases in PAI-1 antigen in the media and in PAI-1 mRNA levels. Induction of PAI-1 mRNA expression by Ang II was not inhibited by pretreating BAECs with either Dup 753 or [Sar1, Ile8]-Ang II, agents that are known to compete effectively for binding to the two major angiotensin receptor subtypes. These data indicate that Ang II regulates the expression of PAI-1 in cultured endothelial cells and that this response is mediated via a pharmacologically distinct form of the angiotensin receptor.

Full text

PDF
999

Images in this article

999Image
on p.999
999Image
on p.999
1000Image
on p.1000
1000Image
on p.1000

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aillaud M. F., Juhan-Vague I., Alessi M. C., Marecal M., Vinson M. F., Arnaud C., Vague P., Collen D. Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost. 1985 Aug 30;54(2):466–468. [PubMed] [Google Scholar]
  2. Alessi M. C., Declerck P. J., De Mol M., Nelles L., Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem. 1988 Aug 15;175(3):531–540. doi: 10.1111/j.1432-1033.1988.tb14225.x. [DOI] [PubMed] [Google Scholar]
  3. Bell L., Madri J. A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990 Jul;137(1):7–12. [PMC free article] [PubMed] [Google Scholar]
  4. Booyse F. M., Sedlak B. J., Rafelson M. E., Jr Culture of arterial endothelial cells: characterization and growth of bovine aortic cells. Thromb Diath Haemorrh. 1975 Dec 15;34(3):825–839. [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  6. Caldwell P. R., Seegal B. C., Hsu K. C., Das M., Soffer R. L. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976 Mar 12;191(4231):1050–1051. doi: 10.1126/science.175444. [DOI] [PubMed] [Google Scholar]
  7. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Bard J. M., Bara L., Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992 Oct 15;359(6396):641–644. doi: 10.1038/359641a0. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Crutchley D. J., Conanan L. B. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem. 1986 Jan 5;261(1):154–159. [PubMed] [Google Scholar]
  10. Declerck P. J., Alessi M. C., Verstreken M., Kruithof E. K., Juhan-Vague I., Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988 Jan;71(1):220–225. [PubMed] [Google Scholar]
  11. Engebretsen L. F., Kierulf P., Brandtzaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res. 1986 Jun 1;42(5):713–716. doi: 10.1016/0049-3848(86)90351-8. [DOI] [PubMed] [Google Scholar]
  12. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991 Feb 5;266(4):2459–2465. [PubMed] [Google Scholar]
  13. Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
  14. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  15. Gimbrone M. A., Jr, Alexander R. W. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science. 1975 Jul 18;189(4198):219–220. doi: 10.1126/science.1138377. [DOI] [PubMed] [Google Scholar]
  16. Gimbrone M. A., Jr Culture of vascular endothelium. Prog Hemost Thromb. 1976;3:1–28. [PubMed] [Google Scholar]
  17. Griendling K. K., Murphy T. J., Alexander R. W. Molecular biology of the renin-angiotensin system. Circulation. 1993 Jun;87(6):1816–1828. doi: 10.1161/01.cir.87.6.1816. [DOI] [PubMed] [Google Scholar]
  18. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985 Dec 19;313(25):1557–1563. doi: 10.1056/NEJM198512193132501. [DOI] [PubMed] [Google Scholar]
  19. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., Blombäck M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 Jul 4;2(8549):3–9. doi: 10.1016/s0140-6736(87)93050-9. [DOI] [PubMed] [Google Scholar]
  20. Heaton J. H., Dame M. K., Gelehrter T. D. Thrombin induction of plasminogen activator inhibitor mRNA in human umbilical vein endothelial cells in culture. J Lab Clin Med. 1992 Aug;120(2):222–228. [PubMed] [Google Scholar]
  21. Johnston C. I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs. 1990;39 (Suppl 1):21–31. doi: 10.2165/00003495-199000391-00005. [DOI] [PubMed] [Google Scholar]
  22. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui H., Hamakubo T., Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993 Nov 25;268(33):24543–24546. [PubMed] [Google Scholar]
  23. Kluft C., Verheijen J. H., Jie A. F., Rijken D. C., Preston F. E., Sue-Ling H. M., Jespersen J., Aasen A. O. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest. 1985 Nov;45(7):605–610. doi: 10.3109/00365518509155267. [DOI] [PubMed] [Google Scholar]
  24. Levin J., Bang F. B. Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh. 1968 Mar 31;19(1):186–197. [PubMed] [Google Scholar]
  25. Lilly L. S., Pratt R. E., Alexander R. W., Larson D. M., Ellison K. E., Gimbrone M. A., Jr, Dzau V. J. Renin expression by vascular endothelial cells in culture. Circ Res. 1985 Aug;57(2):312–318. doi: 10.1161/01.res.57.2.312. [DOI] [PubMed] [Google Scholar]
  26. Loskutoff D. J., van Mourik J. A., Erickson L. A., Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A. 1983 May;80(10):2956–2960. doi: 10.1073/pnas.80.10.2956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Morgan-Boyd R., Stewart J. M., Vavrek R. J., Hassid A. Effects of bradykinin and angiotensin II on intracellular Ca2+ dynamics in endothelial cells. Am J Physiol. 1987 Oct;253(4 Pt 1):C588–C598. doi: 10.1152/ajpcell.1987.253.4.C588. [DOI] [PubMed] [Google Scholar]
  28. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R. E., Dzau V. J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993 Nov 25;268(33):24539–24542. [PubMed] [Google Scholar]
  29. Murphy T. J., Alexander R. W., Griendling K. K., Runge M. S., Bernstein K. E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991 May 16;351(6323):233–236. doi: 10.1038/351233a0. [DOI] [PubMed] [Google Scholar]
  30. Olson J. A., Jr, Shiverick K. T., Ogilvie S., Buhi W. C., Raizada M. K. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1928–1932. doi: 10.1073/pnas.88.5.1928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pannekoek H., Veerman H., Lambers H., Diergaarde P., Verweij C. L., van Zonneveld A. J., van Mourik J. A. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J. 1986 Oct;5(10):2539–2544. doi: 10.1002/j.1460-2075.1986.tb04532.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Patel J. M., Yarid F. R., Block E. R., Raizada M. K. Angiotensin receptors in pulmonary arterial and aortic endothelial cells. Am J Physiol. 1989 May;256(5 Pt 1):C987–C993. doi: 10.1152/ajpcell.1989.256.5.C987. [DOI] [PubMed] [Google Scholar]
  33. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  34. Ridker P. M., Gaboury C. L., Conlin P. R., Seely E. W., Williams G. H., Vaughan D. E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993 Jun;87(6):1969–1973. doi: 10.1161/01.cir.87.6.1969. [DOI] [PubMed] [Google Scholar]
  35. Ridker P. M., Vaughan D. E., Stampfer M. J., Manson J. E., Shen C., Newcomer L. M., Goldhaber S. Z., Hennekens C. H. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. 1992 May;85(5):1822–1827. doi: 10.1161/01.cir.85.5.1822. [DOI] [PubMed] [Google Scholar]
  36. Rånby M., Bergsdorf N., Nilsson T., Mellbring G., Winblad B., Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem. 1986 Dec;32(12):2160–2165. [PubMed] [Google Scholar]
  37. Sasaki K., Yamano Y., Bardhan S., Iwai N., Murray J. J., Hasegawa M., Matsuda Y., Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991 May 16;351(6323):230–233. doi: 10.1038/351230a0. [DOI] [PubMed] [Google Scholar]
  38. Sawdey M., Podor T. J., Loskutoff D. J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989 Jun 25;264(18):10396–10401. [PubMed] [Google Scholar]
  39. Schleef R. R., Higgins D. L., Pillemer E., Levitt L. J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989 May;83(5):1747–1752. doi: 10.1172/JCI114076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schneiderman J., Sawdey M. S., Keeton M. R., Bordin G. M., Bernstein E. F., Dilley R. B., Loskutoff D. J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6998–7002. doi: 10.1073/pnas.89.15.6998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smith D., Gilbert M., Owen W. G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985 Oct;66(4):835–839. [PubMed] [Google Scholar]
  42. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  43. Swanson G. N., Hanesworth J. M., Sardinia M. F., Coleman J. K., Wright J. W., Hall K. L., Miller-Wing A. V., Stobb J. W., Cook V. I., Harding E. C. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept. 1992 Aug 13;40(3):409–419. doi: 10.1016/0167-0115(92)90527-2. [DOI] [PubMed] [Google Scholar]
  44. Thomas P. S. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201–5205. doi: 10.1073/pnas.77.9.5201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. White B. A., Bancroft F. C. Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples. J Biol Chem. 1982 Aug 10;257(15):8569–8572. [PubMed] [Google Scholar]
  46. Wright R. A., Flapan A. D., Alberti K. G., Ludlam C. A., Fox K. A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994 Jul;24(1):67–73. doi: 10.1016/0735-1097(94)90543-6. [DOI] [PubMed] [Google Scholar]
  47. Yusuf S., Pepine C. J., Garces C., Pouleur H., Salem D., Kostis J., Benedict C., Rousseau M., Bourassa M., Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992 Nov 14;340(8829):1173–1178. doi: 10.1016/0140-6736(92)92889-n. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES